← Klinické štúdie • Chronická choroba obličiek
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
Nábor prebieha
• Fáza 3 • intervenčná • NCT07241390
Stručný súhrn
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Základné údaje
| Ochorenia | Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease |
|---|---|
| Intervencie |
DRUG: Orforglipron DRUG: Placebo |
| Sponzor | Eli Lilly and Company |
| Plánovaný počet | 7140 |
| Začiatok | 2025-12-01 |
| Predp. ukončenie (primárne) | 2031-08-01 |
| Krajiny | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Estonia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Romania, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Tunisia, Turkey (Türkiye), Ukraine, United Kingdom |
| Posledná aktualizácia | 2026-06-23 |
Upozornenie: údaje sú orientačné a podliehajú zmenám. Úplné vstupné/vylučovacie
kritériá, kontakty a aktuálny stav nájdete v oficiálnom registri. Tento prehľad
nenahrádza lekársku konzultáciu.